> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Gets Permanent Injunction Against VivaCeuticals
- URL: https://www.fdaweb.com/fda-gets-permanent-injunction-against-vivaceuticals/
- Published: 2017-01-19T12:00:00.000Z
- Updated: 2026-09-14T22:01:44.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5137777

Acting for FDA, the Justice Department filed action in a California federal court seeking a permanent injunction against VivaCeuticals, Inc., doing business as Regeneca Worldwide, and its CEO **Matthew Nicosia**. A department [news release](https://www.justice.gov/opa/pr/united-states-files-consent-decree-permanent-injunction-against-california-dietary-supplement?ref=fdaweb.com) says the company and Nicosia have agreed to cease all operations as part of a settlement.

The complaint says the defendants violated the Federal Food, Drug, and Cosmetic Act (FFDCA) by failing to manufacture dietary supplements in accordance with FDA’s current good manufacturing practice regulations. It says the defendants manufactured and distributed RegeneSlim Appetite Control that contained the unsafe food additive 1,3 dimethylamylamine (DMAA) and failed to disclose its presence in the RegeneSlim labeling, causing the product to be an unapproved new drug and a misbranded drug.

“The government’s enforcement action resulted from a series of FDA inspections of the defendants’ manufacturing facility that found recurring FFDCA violations of the same nature as those alleged in the complaint, and which the defendants failed to correct despite FDA warnings,” the release says.

The consent decree accepted by the defendants permanently prohibits them from violating the FFDCA. They are required to cease all operations and, if they wish to resume manufacturing dietary supplements or drugs in the future, obtain FDA determination that their manufacturing practices comply with the law.